Johnson & Johnson (JNJ)
162.98
-1.80 (-1.09%)
NYSE · Last Trade: Jul 18th, 2:37 AM EDT
Detailed Quote
Previous Close | 164.78 |
---|---|
Open | 163.18 |
Bid | 163.50 |
Ask | 164.84 |
Day's Range | 162.30 - 164.70 |
52 Week Range | 140.68 - 169.99 |
Volume | 11,295,768 |
Market Cap | 428.42B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (3.19%) |
1 Month Average Volume | 9,119,643 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Shares of Johnson & Johnson broke out of a classic ascending triangle pattern. They have since stalled out at resistance.
Via Benzinga · July 17, 2025
Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility
Via MarketBeat · July 17, 2025
Johnson & Johnson earnings came in 3% higher than consensus. The company's operating leverage was "slightly diluted by higher tax."
Via Benzinga · July 17, 2025
Via Benzinga · July 17, 2025
Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin Trust ETF and Joseph Terranova chooses Intercontinental Exchange, with Piper Sandler raising price target for ICE. Johnson & Johnson's FY2025 earnings guidance rose, while iShares Bitcoin Trust ETF and Intercontinental Exchange shares saw varied movement.
Via Benzinga · July 17, 2025
Via The Motley Fool · July 17, 2025
Johnson & Johnson hinted at leveraging tariff delays to maintain its outlook; however, Jim Cramer credited the performance to lower tariffs.
Via Benzinga · July 17, 2025
Powell Panic, Pharma Power & a PEW Parade: Wall Street’s Wild Wednesday
Via Chartmill · July 17, 2025
Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff policy.
Via Stocktwits · July 16, 2025
U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78.
Via Benzinga · July 16, 2025
Via The Motley Fool · July 16, 2025
Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.
Via MarketBeat · July 16, 2025
Volatility surged across interest rate-sensitive assets Wednesday after reports circulated that President Donald Trump may be preparing to remove Federal Reserve Chair Jerome Powell from his post. The rumors sparked fears over the Fed's independ
Via Benzinga · July 16, 2025
Via Benzinga · July 16, 2025
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Via Chartmill · July 16, 2025
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company’s full-year revenue guidance of $93.3 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 3.2% above analysts’ consensus estimates.
Via StockStory · July 16, 2025
The company also easily beat second-quarter adjusted earnings and sales forecasts.
Via Investor's Business Daily · July 16, 2025
Johnson & Johnson beat Q2 estimates and raised its 2025 outlook, driven by strong cancer and MedTech sales despite Stelara declines.
Via Benzinga · July 16, 2025